Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68831 | 0.95 | PIK3CG (0.59) | PIK3CGPIK3CACDK5PIK3CBCDK4 | |
| SCHEMBL69361 | 0.92 | GSK3B (0.48) | PIK3CGPIK3CACDK5PIK3CBCDK4 | |
| SCHEMBL69405 | 0.85 | BRAF (0.44) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL69636 | 0.85 | BRAF (0.52) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL67437 | 0.84 | MAPK14 (0.53) | CDK2MAPK14MAPK13RAF1MAPK9 | |
| SCHEMBL13693370 | 0.83 | BRAF (0.51) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL68793 | 0.81 | MAPK14 (0.68) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL13693257 | 0.80 | MAPK14 (0.38) | MAPK14MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL66921 | 0.79 | BRAF (0.44) | PIK3CGPIK3CAMAPK14MAPK13RAF1 | |
| SCHEMBL68688 | 0.79 | IGF1R (0.49) | PIK3CGPIK3CACDK5PIK3CBCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | PIK3CG 222/4885PIK3CA 30/4885CDK5 109/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | PIK3CG 124/4885PIK3CA 45/4885CDK5 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.